Kimmo Porkka M.D, Ph.D. is a professor of clinical hematology at the University of Helsinki and his current clinical position is Head of the Hematology Division at the Helsinki University Central Hospital. Prof. Porkka received his medical degrees at the Universities of Turku and Helsinki. He has received clinical training in oncology, internal medicine and hematology.
Prof. Porkka's research experience includes clinical epidemiology, clinical breast cancer research, human molecular genetics (genetic mapping of complex diseases), basic and applied cancer research on characterization of leukemia-specific proteins and ligands (post-doctoral visit at the Burnham Institute, La Jolla, USA). Prof. Porkka's recent research interest relate to molecularly targeted therapies and immunotherapy of hematological malignancies. He has been the principal investigator in several Phase I-III clinical studies (academic and company-sponsored) on chronic myeloid leukemia and acute lymphoblastic/myeloid leukemia and performed closely linked basic science projects on leukemic stem cell targeting and immunomodulatory effects of tyrosine kinase inhibitors at the Hematology Research Unit Helsinki.
Prof. Porkka is the principal investigator in the Finnish Hematology Registry and Biobank (FHRB; hematology.fi/fhrb), which is a national, population-based registry and biobanking effort commencing in 2011. The first scientific project utilizing the FHRB is an in vitro highthroughput drug screening and molecular profiling on primary cells aiming in individually tailored therapy for relapsed or refractory AML. Prof. Porkka has more than 90 original publications in international peer reviewed journals, such as New England Journal of Medicine, Nature Medicine, Nature Genetics, PNAS, Journal of Clinical Oncology, Blood and Leukemia. Prof Porkka`s main collaborators include prof. Bengt Simonsson and the Nordic CML Study Group, prof. Olli Kallioniemi, Finnish Institute for Molecular Medicine (highthroughput compound screening in acute leukemia, molecular profiling), Dr. Kari Aranko, Finnish Red Cross Blood Service (leukemia biobanking), Dr. Petteri Arstila, Haartman Institute, Dept. of Immunology, Univ. of Helsinki, Finland (T-cell immunology), Dr. Ruth Seggewiss, Univ. of Wurtzburg, Germany (transplantation and clinical immunology) and Bristol-Myers Squibb, Celgene, Novartis and Pfizer (Phase I-III drug studies, basic research).